Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Phenazopyridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 8/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | HBB | P68871 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenazopyridine SCHEMBL360809 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1CYP3A4 | |
| Phenazopyridine SCHEMBL14340038 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1CYP3A4 | |
| Phenazopyridine SCHEMBL27863926 | 0.98 | MEN1 (0.96) | MEN1KMT2AMAPK1TDP1CYP3A4 | |
| Phenazopyridine SCHEMBL26499 | 0.98 | MAPT (1.00) | MEN1KMT2AMAPK1TDP1CYP3A4 | |
| Phenazopyridine SCHEMBL215655 | 0.98 | MAPT (1.00) | MEN1KMT2AMAPK1TDP1CYP3A4 | |
| Phenazopyridine SCHEMBL29392321 | 0.98 | MAPT (1.00) | MEN1KMT2AMAPK1TDP1CYP3A4 | |
| Phenazopyridine SCHEMBL19357 | 0.98 | MAPT (1.00) | MEN1KMT2AMAPK1TDP1CYP3A4 | |
| Phenazopyridine SCHEMBL14687482 | 0.98 | MAPT (1.00) | MEN1KMT2AMAPK1TDP1CYP3A4 | |
| Phenazopyridine SCHEMBL28796595 | 0.98 | MAPT (1.00) | MEN1KMT2AMAPK1TDP1CYP3A4 | |
| Phenazopyridine SCHEMBL301672 | 0.96 | MAPT (0.96) | MEN1KMT2AMAPK1TDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5185 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091119-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | CELLIS AG (CH) | 2026-04-02 | — | — | US | claimed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| EP-3699174-B1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2025-11-12 | — | — | EP | claimed |
| EP-4637829-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF OVARIAN CANCER | Cellis Sp. z o.o. ([Ltd.] (PL) | 2025-10-29 | — | — | EP | claimed |
| US-12448559-B1 | Puddle job with delayed setting of resin via a polymerization reaction with an activator | HALLIBURTON ENERGY SERVICES, INC. (US) | 2025-10-21 | — | — | US | claimed |
| EP-4594520-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2025-08-06 | — | — | EP | claimed |
| EP-4587062-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | Cellis AG (CH) | 2025-07-23 | — | — | EP | claimed |
| US-20250205278-A1 | METHODS AND COMPOSITIONS FOR WOUND HEALING | ABBOTT NICHOLAS L (US) | 2025-06-26 | — | — | US | claimed |
| WO-2025111413-A1 | TREATMENT FOR SKIN DISORDERS | Mycotechnology, Inc. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-113227752-B | Enhanced, rapid, homogeneous cell staining and assay | 上海宜晟生物科技有限公司 | 2025-04-29 | — | — | CN | claimed |
| EP-0735861-A1 | TISSUE MOISTURIZING AND ANTIMICROBIAL COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1996-10-09 | — | — | EP | claimed |
| EP-0110955-B1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIV FLORIDA (US) | 1995-08-23 | — | — | EP | claimed |
| WO-1995017175-A1 | ANTIMICROBIAL WIPE COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1995-06-29 | — | — | WO | claimed |
| WO-1995017165-A2 | TISSUE MOISTURIZING AND ANTIMICROBIAL COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1995-06-29 | — | — | WO | claimed |
| EP-0599188-A1 | Trans and CIS traumatic acid salts having cicatrizant activity associated to bacteriostatic, antiviral, antibiotic or antifungal activity | LIFEGROUP S.p.A. (IT) | 1994-06-01 | — | — | EP | claimed |
| EP-0312132-B1 | VETERINARY AND HUMAN MEDICAL REMEDY HAVING AN ANTIVIRAL AND ANTITUMOROUS ACTIVITY, CONTAINING 2,6-DIAMINO-3-PHENYL-AZO-PYRIDINE | Hak, Barend Willem (NL) | 1993-01-13 | — | — | EP | claimed |
| EP-0312132-A2 | Veterinary and human medical remedy having an antiviral and antitumorous activity, containing 2,6-diamino-3-phenyl-azo-pyridine | Hak, Barend Willem (NL) | 1989-04-19 | — | — | EP | claimed |
| EP-0222425-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-05-20 | — | — | EP | claimed |
| EP-0218300-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-04-15 | — | — | EP | claimed |
| US-4393127-A | Structure with a silicon body having through openings | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 1983-07-12 | — | — | US | claimed |